PRME · Prime Medicine Inc
United States · RS rating 93 · As of 2026-11-03
| Price | 4.55 USD |
|---|---|
| 1-day change | +2.5% |
| RS rating (overall / 1M / 3M / 12M) | 93 / 97 / 95 / 45 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 38 / 46 / 64 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +14.3% |
| Sales growth Q/Q | -31.6% |
| Distance from 52-week high | +15.1% |
| Market cap (USD) | $693.3M |